China Opens New Registration Regs For Comment, Industry Urged To 'Weigh In'
Following the passing of a new Pharmaceutical Administration Law, which will take effect on 1 December, China’s National Medical Products Administration has now released a second draft of its Drug Registration Regulations, and observers are urging stakeholders to actively submit comments on the highly important framework.
You may also be interested in...
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.